TY - JOUR
T1 - Roles of heterotypic CCN2/CTGF-CCN3/NOV and homotypic CCN2-CCN2 interactions in expression of the differentiated phenotype of chondrocytes
AU - Hoshijima, Mitsuhiro
AU - Hattori, Takako
AU - Aoyama, Eriko
AU - Nishida, Takashi
AU - Yamashiro, Takashi
AU - Takigawa, Masaharu
PY - 2012/10
Y1 - 2012/10
N2 - To identify proteins that regulate CCN2 activity, we carried out GAL4-based yeast two-hybrid screening with a cDNA library derived from a chondrocytic cell line, HCS-2/8. CCN2/CTGF and CCN3/NOV polypeptides were picked up as CCN2-binding proteins, and CCN2-CCN2 and CCN2-CCN3 binding domains were identified. Direct binding between CCN2 and CCN3 was confirmed by coimmunoprecipitation in vitro and in vivo and surface plasmon resonance, and the calculated dissociation constants (Kd) were 1.17 × 10 -9 m for CCN2 and CCN2, and 1.95 × 10-9 m for CCN2 and CCN3. Ectopically overexpressed green fluorescent protein-CCN2 and Halo-CCN3 in COS7 cells colocalized, as determined by direct fluorescence analysis. We present evidence that CCN2-CCN3 interactions modulated CCN2 activity such as enhancement of ACAN and col2a1 expression. Curiously, CCN2 enhanced, whereas CCN3 inhibited, the expression of aggrecan and col2a1 mRNA in HCS-2/8 cells, and combined treatment with CCN2 and CCN3 abolished the inhibitory effect of CCN3. These effects were neutralized with an antibody against the von Willebrand factor type C domain of CCN2 (11H3). This antibody diminished the binding between CCN2 and CCN2, but enhanced that between CCN3 and CCN2. Our results suggest that CCN2 could form homotypic and heterotypic dimers with CCN2 and CCN3, respectively. Strengthening the binding between CCN2 and CCN3 with the 11H3 antibody had an enhancing effect on aggrecan expression in chondrocytes, suggesting that CCN2 had an antagonizing effect by binding to CCN3. To identify proteins that regulate CCN2 activity in chondrocytes, yeast two-hybrid screenings identified CCN2 and CCN3, and their binding domains were estimated. Direct binding between CCN2 and CCN3 was confirmed in vitro and in vivo. CCN2 enhanced, whereas CCN3 inhibited, the expression of cartilaginous matrix genes; and the combined treatment with CCN2 and CCN3 abolished the inhibitory effect by CCN3.
AB - To identify proteins that regulate CCN2 activity, we carried out GAL4-based yeast two-hybrid screening with a cDNA library derived from a chondrocytic cell line, HCS-2/8. CCN2/CTGF and CCN3/NOV polypeptides were picked up as CCN2-binding proteins, and CCN2-CCN2 and CCN2-CCN3 binding domains were identified. Direct binding between CCN2 and CCN3 was confirmed by coimmunoprecipitation in vitro and in vivo and surface plasmon resonance, and the calculated dissociation constants (Kd) were 1.17 × 10 -9 m for CCN2 and CCN2, and 1.95 × 10-9 m for CCN2 and CCN3. Ectopically overexpressed green fluorescent protein-CCN2 and Halo-CCN3 in COS7 cells colocalized, as determined by direct fluorescence analysis. We present evidence that CCN2-CCN3 interactions modulated CCN2 activity such as enhancement of ACAN and col2a1 expression. Curiously, CCN2 enhanced, whereas CCN3 inhibited, the expression of aggrecan and col2a1 mRNA in HCS-2/8 cells, and combined treatment with CCN2 and CCN3 abolished the inhibitory effect of CCN3. These effects were neutralized with an antibody against the von Willebrand factor type C domain of CCN2 (11H3). This antibody diminished the binding between CCN2 and CCN2, but enhanced that between CCN3 and CCN2. Our results suggest that CCN2 could form homotypic and heterotypic dimers with CCN2 and CCN3, respectively. Strengthening the binding between CCN2 and CCN3 with the 11H3 antibody had an enhancing effect on aggrecan expression in chondrocytes, suggesting that CCN2 had an antagonizing effect by binding to CCN3. To identify proteins that regulate CCN2 activity in chondrocytes, yeast two-hybrid screenings identified CCN2 and CCN3, and their binding domains were estimated. Direct binding between CCN2 and CCN3 was confirmed in vitro and in vivo. CCN2 enhanced, whereas CCN3 inhibited, the expression of cartilaginous matrix genes; and the combined treatment with CCN2 and CCN3 abolished the inhibitory effect by CCN3.
KW - ACAN
KW - CCN2/CTGF
KW - CCN3/NOV
KW - chondrocyte
KW - dimerization
UR - http://www.scopus.com/inward/record.url?scp=84866344934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866344934&partnerID=8YFLogxK
U2 - 10.1111/j.1742-4658.2012.08717.x
DO - 10.1111/j.1742-4658.2012.08717.x
M3 - Article
C2 - 22812570
AN - SCOPUS:84866344934
SN - 1742-464X
VL - 279
SP - 3584
EP - 3597
JO - FEBS Journal
JF - FEBS Journal
IS - 19
ER -